Video

Dr. Richard Silver Discusses the High Cost of Drugs in CML

Richard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia (CML).

Overall, Silver believes that the cost of drugs to treat CML is too high. Additionally, in the majority of patients, he remains unconvinced that other agents work as well as imatinib, which will soon be off patent.

To select the most appropriate treatment, it remains important for a physician to discuss costs as well as risk factors with a patient. Silver notes that in general, he prescribes imatinib to approximately two-thirds of his patients with CML and will continue to do so, specifically as a generic version becomes available.

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,
Brian I. Rini, MD, FASCO
Marc-Oliver Grimm, MD
David Samuel Dicapua Siegel, MD
Moritz Fürstenau, MD
Joseph Franses, MD, PhD